Get Your Health Score
Nocturia And Its Relationship With Prostate Conditions
Published on: April 30, 2025
Nocturia And Its Relationship With Prostate Conditions
  • Article reviewer photo

    Elsa Fetoshi

    MSc Health Psychology, King’s College London

  • Article reviewer photo

    Editor Name

    Doctor of Philosophy(PhD), St George's, University of London

Introduction

Nocturia, a condition characterised by waking up during the night to urinate, is a common and often disruptive problem, particularly among older adults. The prevalence of nocturia increases with age, affecting an estimated 70-80% of people assigned male at birth (AMAB) over 60 years old.6 This condition significantly impacts quality of life by disrupting sleep, which can lead to daytime fatigue, decreased productivity, and an increased risk of accidents and falls.19

Understanding nocturia

Physiological mechanism

Nocturia involves the kidneys producing more urine at night or the bladder being unable to hold urine long enough during sleep. Normally, antidiuretic hormone (ADH) reduces urine production at night. However, this balance can be disrupted by various factors, including age-related changes, which may lead to increased nocturnal urine production.

Common causes

Several factors can cause nocturia, including excessive fluid intake before bedtime, certain medications (like diuretics), and various health conditions such as diabetes and heart failure. However, in people AMAB, prostate conditions are a particularly common cause.4

Prostate conditions and nocturia

Overview of prostate anatomy and function

The prostate is a small gland in people AMAB that surrounds the urethra, the tube through which urine passes out of the body. It plays a crucial role in producing seminal fluid. As these people age, the prostate can enlarge or become inflamed, leading to urinary symptoms including nocturia.1

Prostate enlargement (benign prostatic hyperplasia - BPH)

BPH is a non-cancerous enlargement of the prostate gland, common in older people AMAB. This condition can compress the urethra, causing urinary symptoms such as increased frequency, urgency, and nocturia.16 Research shows that up to 50% of men in their 50s and 90% of people AMAB  in their 80s may experience BPH.2

The mechanism by which BPH causes nocturia involves both increased bladder outlet resistance and changes in bladder function. The enlarged prostate can obstruct urine flow, leading to incomplete bladder emptying and residual urine, which in turn prompts more frequent urination, especially at night.17

Prostate inflammation (prostatitis)

Prostatitis refers to inflammation of the prostate gland and can be acute or chronic. Acute bacterial prostatitis is characterised by severe symptoms, including fever and chills, while chronic prostatitis may present with more subtle symptoms such as pelvic pain and urinary difficulties, including nocturia.14 Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common type that can significantly affect a person's quality of life by causing persistent discomfort and urinary issues.8

Prostate cancer

Prostate cancer is one of the most common cancers in people AMAB. It can cause urinary symptoms similar to those of BPH, including nocturia. Treatments for prostate cancer, such as surgery, radiation, and hormone therapy, can also affect urinary function and contribute to nocturia. For instance, radical prostatectomy, a common surgical treatment, can lead to urinary incontinence and frequent urination.22

Diagnosis and assessment

Medical history and symptom evaluation

A comprehensive medical history and symptom evaluation are essential in diagnosing nocturia and its underlying causes. Physicians will ask about the frequency and volume of nighttime urination, fluid intake, and other urinary symptoms. They may also inquire about related symptoms, such as pain or changes in urine flow, which can provide clues about prostate conditions.5

Diagnostic tests

To diagnose nocturia and its relation to prostate conditions, several tests may be conducted:

Urinalysis: This test can detect infections, blood, and other abnormalities in the urine.

Bladder Diary: Patients record their urination patterns, including timing and volume, which helps in identifying the severity and potential causes of nocturia.

Prostate-Specific Antigen (PSA) Test: Elevated PSA levels can indicate prostate enlargement, inflammation, or cancer.

Digital Rectal Exam (DRE): This physical exam allows the physician to feel the size and texture of the prostate gland.

Imaging Studies: Ultrasound or MRI may be used to visualise the prostate and urinary tract.

Treatment and management

Lifestyle and behavioural modifications

Lifestyle changes can significantly alleviate nocturia. Recommendations include reducing fluid intake before bedtime, limiting alcohol and caffeine consumption, and practising bladder training exercises. Maintaining a healthy weight and managing other health conditions, such as diabetes, can also help reduce nocturia symptoms.

Medications

Medications play a vital role in managing nocturia, particularly when related to prostate conditions. For BPH, alpha-blockers (such as tamsulosin) can relax the muscles of the prostate and bladder neck, improving urine flow and reducing nocturia. 5-alpha-reductase inhibitors (such as finasteride) can shrink the prostate over time, providing longer-term relief.23

For prostatitis, antibiotics are used to treat bacterial infections, while anti-inflammatory medications and alpha-blockers can help manage chronic prostatitis symptoms.14

Surgical and minimally invasive procedures

When medications are insufficient, surgical and minimally invasive procedures may be considered. Transurethral resection of the prostate (TURP) is a common surgical procedure for BPH that removes part of the prostate to relieve obstruction. Other options include laser therapy and newer minimally invasive techniques such as UroLift and Rezūm, which aim to reduce symptoms with less recovery time.

Managing underlying prostate conditions

Specific treatments for prostate conditions can also help manage nocturia. For instance, advanced prostate cancer may be treated with surgery, radiation, or hormone therapy, each of which has implications for urinary function. Managing these treatments effectively can help mitigate nocturia.

Research and future directions

Recent studies and findings

Recent research has provided deeper insights into the relationship between nocturia and prostate conditions. Studies have highlighted the importance of early detection and treatment of BPH and prostatitis to prevent the progression of symptoms, including nocturia. Additionally, research into the molecular mechanisms of prostate growth and inflammation is ongoing, potentially leading to new therapeutic targets.12

Emerging treatments and technologies

New medications and technologies are continually being developed to improve the management of nocturia and prostate conditions. For instance, combination therapies that use both alpha-blockers and 5-alpha-reductase inhibitors have shown promise in providing more comprehensive symptom relief for BPH.17 Innovations in minimally invasive procedures also offer less invasive options with faster recovery times and fewer complications.24

Holistic and integrative approaches

Integrative medicine approaches, including acupuncture, phytotherapy, and lifestyle interventions, are gaining attention for their potential benefits in managing nocturia and prostate conditions. These holistic treatments can complement traditional medical therapies, offering additional avenues for symptom relief and overall well-being.25

Summary

Nocturia is a common and disruptive condition closely linked to prostate health. Understanding the relationship between nocturia and prostate conditions such as BPH, prostatitis, and prostate cancer is essential for effective diagnosis and treatment. By combining lifestyle modifications, medications, and advanced medical procedures, patients can achieve better management of nocturia and improve their quality of life. Ongoing research and emerging treatments hold promise for even more effective solutions in the future. It is crucial for individuals experiencing nocturia to seek medical consultation to determine the underlying cause and appropriate treatment.

Reference

  1. Barry MJ. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urology. 2001 Dec;58(6 Suppl 1):25–32; discussion 32. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0090429501013000
  2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984 Sep;132(3):474–9. Available from: http://www.jurology.com/doi/10.1016/S0022-5347%2817%2949698-4
  3. Trumbeckas D, Milonas D, Jievaltas M, Matjosaitis AJ, Kincius M, Grybas A, et al. Importance of prostate volume and urinary flow rate in prediction of bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia. Cent European J Urol [Internet]. 2011 [cited 2024 Jul 19];64(2):75–9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921710/
  4. Hofmeester I, Kollen BJ, Steffens MG, Bosch JLHR, Drake MJ, Weiss JP, et al. The association between nocturia and nocturnal polyuria in clinical and epidemiological studies: a systematic review and meta-analyses. Journal of Urology [Internet]. 2014 Apr [cited 2024 Jul 19];191(4):1028–33. Available from: http://www.jurology.com/doi/10.1016/j.juro.2013.10.100
  5. Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology. 2006 Aug;68(2):318–23. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0090429506007400
  6. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006 Dec;50(6):1306–14; discussion 1314-1315. Available from: https://linkinghub.elsevier.com/retrieve/pii/S030228380601116X
  7. Peng T, Cheng Y, Jin Y, Xu N, Guo T. Acupuncture for chronic prostatitis. Medicine (Baltimore) [Internet]. 2018 Apr 27 [cited 2024 Jul 19];97(17):e0615. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944557/
  8. Krieger JN, Nyberg L, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999 Jul 21;282(3):236–7. Available from: http://jama.ama-assn.org/cgi/doi/10.1001/jama.282.3.236
  9. Kok ET, Schouten BW, Bohnen AM, Groeneveld FPMW, Thomas S, Bosch JLHR. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community-based population of healthy ageing men: the Krimpen Study. J Urol. 2009 Feb;181(2):710–6. Available from: http://www.jurology.com/doi/10.1016/j.juro.2008.10.025
  10. Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017 Jun 27;317(24):2532–42. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2017.7248
  11. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003 Dec 18;349(25):2387–98. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa030656
  12. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011 May;185(5):1793–803. Available from: http://www.jurology.com/doi/10.1016/j.juro.2011.01.074
  13. Nickel JC. Prostatitis: myths and realities. Urology. 1998 Mar;51(3):362–6. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0090429597006432
  14. Nickel JC, Downey J, Johnston B, Clark J, Canadian Prostatitis Research Group. Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial. J Urol. 2001 May;165(5):1539–44. Available from: http://www.jurology.com/doi/10.1016/S0022-5347%2805%2966344-6
  15. Weiss JP. Nocturia: focus on aetiology and consequences. Rev Urol [Internet]. 2012 [cited 2024 Jul 24];14(3–4):48–55. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602727/
  16. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013 Jul;64(1):118–40. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0302283813002285
  17. Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S11-18. ​​Available from: https://www.nature.com/articles/ijir200855
  18. Tacklind J, MacDonald R, Rutks I, Stanke JU, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD001423. Available from: https://doi.wiley.com/10.1002/14651858.CD001423.pub3
  19. Tikkinen KAO, Johnson TM, Tammela TLJ, Sintonen H, Haukka J, Huhtala H, et al. Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol. 2010 Mar;57(3):488–96. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0302283809003418
  20. Alcaraz A, Carballido-Rodríguez J, Unda-Urzaiz M, Medina-López R, Ruiz-Cerdá JL, Rodríguez-Rubio F, et al. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment—the QUALIPROST study. Int Urol Nephrol [Internet]. 2016 [cited 2024 Jul 24];48:645–56. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839045/
  21. Nickel JC, Méndez-Probst CE, Whelan TF, Paterson RF, Razvi H. 2010 Update: Guidelines for the management of benign prostatic hyperplasia. Can Urol Assoc J [Internet]. 2010 Oct [cited 2024 Jul 24];4(5):310–6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950766/
  22. Castellan P, Ferretti S, Litterio G, Marchioni M, Schips L. Management of Urinary Incontinence Following Radical Prostatectomy: Challenges and Solutions. Ther Clin Risk Manag [Internet]. 2023 [cited 2025 Apr 29]; 19:43–56. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851058/. 
  23. Roehrborn CG. 5-α-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia. Rev Urol [Internet]. 2003 [cited 2025 Apr 29]; 5(Suppl 5):S12–21. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1502358/. 
  24. Franco JV, Jung JH, Imamura M, Borofsky M, Omar MI, Escobar Liquitay CM, et al. Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta‐analysis. Cochrane Database Syst Rev [Internet]. 2020 [cited 2025 Apr 29]; 2020(6):CD013656. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388921/. 
  25. Abrams DI. An Integrative Approach to Prostate Cancer. J Altern Complement Med. 2018; 24(9–10):872–80. Available from: https://pubmed.ncbi.nlm.nih.gov/30247964/ 
Share

Neeraj Nihal Patnaik

MSc Public Health - University of East London, London

Neeraj is an accomplished health professional with a robust academic and professional background. He holds a Master of Science in Public Health from the University of East London, London United Kingdom where he specialized in epidemiology and global health.

Additionally Neeraj is a pharmacist having earned Master of Pharmacy (MPharm) degree from Jawaharlal Nehru Technological University, Hyderabad India. With a passion for bridging the gap between clinical practice and public health, Neeraj has dedicated his career to improving health outcomes through evidence-based interventions and comprehensive healthcare strategies.

His diverse expertise spans across public health policy, infectious disease control, and pharmaceutical management, allowing him to approach health challenges from a multidisciplinary perspective.

Currently, Neeraj is channeling his extensive knowledge into medical writing, where he crafts high-quality scientific content for various stakeholders, including healthcare professionals, researchers, and policymakers. His work includes developing clinical guidelines, research articles, and educational materials aimed at enhancing public understanding of health issues.

arrow-right